A Retrospective Observational Study on Disease Characteristics and Treatment Patterns of Giant Cell Tumor of the Bone in China
Table 3
Treatment patterns.
Description
FAS ()
UMNAS ()
Primary diagnosis ()
Last disease recurrence ()
Primary diagnosis ()
Last disease recurrence ()
Surgical treatment, (%)
666 (99.7)
196 (98.0)
172 (99.4)
77 (96.3)
Curettage, (%)
457 (68.4)
94 (47.0)
36 (20.8)
8 (10.0)
Resection, (%)
207 (31.0)
98 (49.0)
135 (78.0)
65 (81.3)
Amputation, (%)
1 (0.2)
4 (2.0)
1 (0.6)
4 (5.0)
Others, (%)
1 (0.2)
0 (0.0)
0 (0.0)
0 (0.0)
Any high-morbidity surgery, (%)
111(16.6)
65 (32.5)
111 (64.2)
65 (81.3)
Nonsurgical treatment by objective, (%)
205 (30.7)
67 (33.5)
91 (52.6)
37 (46.3)
Salvage treatment alone, (%)
2 (0.3)
4 (2.0)
1 (0.6)
3 (3.8)
Neoadjuvant therapy, (%)
131 (19.6)
27 (13.5)
48 (27.8)
15 (18.8)
Adjuvant therapy, (%)
30 (4.5)
22 (11.0)
12 (6.9)
13 (16.3)
Neoadjuvant+adjuvant therapy, (%)
42 (6.3)
14 (7.0)
30 (17.3)
6 (7.5)
Nonsurgical treatment+surgical treatment, (%)†
0 (0.0)
1 (0.5)
0 (0.0)
0 (0.0)
Nonsurgical treatment by category, (%)
205 (30.7)
67 (33.5)
91 (52.6)
37 (46.3)
Radiotherapy
18 (2.7)
2 (1.0)
18 (10.4)
2 (2.5)
Bisphosphonates
180 (26.9)
61 (30.5)
66 (38.2)
33 (41.3)
Chemotherapy
0 (0.0)
1 (0.5)
0 (0.0)
1 (1.3)
Serial arterial embolization
45 (6.7)
8 (4.0)
43 (24.9)
6 (7.5)
Includes joint resection/joint replacement, amputation, or other surgical procedure leading to severe morbidity after surgery. †First-line nonsurgical treatment failed, so the patient was subsequently treated with surgery. FAS = full analysis set; UMNAS = unmet medical needs analysis set.
